-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

Benzinga·10/07/2026 15:19:07
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.